Clinical Trials

590 enrolled 12 charts 2 FDA

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02339922 2026-03-05

Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma

33 enrolled 16 charts

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04075292 2026-03-05

Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia

155 enrolled 16 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04285567 2026-03-03

CRISTALLO

Phase 3 Completed

166 enrolled 27 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06364423 2026-03-02

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias

Phase 1/2 Recruiting

132 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03609593 2026-02-25

Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia

Phase 2 Completed

42 enrolled

Phase 1/2 Active not recruiting

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02158091 2026-02-13

A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL

32 enrolled 11 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06644183 2026-02-11

Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)

Phase 1/2 Recruiting

64 enrolled

Leukemia, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02970318 2026-02-06

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

310 enrolled 18 charts 2 FDA

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04965493 2026-01-29

BRUIN CLL-322

600 enrolled

Hematologic Diseases, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT01446133 2026-01-27

Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)

120 enrolled

LymphoidOther hematologic neoplasmSarcoma

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03740529 2026-01-27

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

Phase 1/2 Completed

803 enrolled 4 FDA

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Dendritic Cell Sarcoma, Interdigitating

NCT05023980 2026-01-22

BRUIN CLL-313

309 enrolled

Phase 1 Active not recruiting

Hematologic Diseases, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT04843904 2026-01-07

SAVE

40 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06970743 2026-01-07

CaDAnCe-303

Phase 3 Recruiting

150 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02296918 2025-12-19

Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL

Phase 1 Completed

69 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic

NCT02048813 2025-11-28

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

529 enrolled 12 charts 3 FDA

Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT06839053 2025-11-19

Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma

Phase 2 Recruiting

20 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT02007044 2025-11-06

Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia

66 enrolled

Phase 1 Not yet recruiting

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic

NCT07225439 2025-11-06

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

15 enrolled

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT02251548 2025-10-24

iFCR

85 enrolled 17 charts

Phase 1 Active not recruiting

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04981912 2025-10-15

Rituximab + High-Dose Methylprednisolone Debulking Prior to Venetoclax for CLL & SLL Patients

4 enrolled 8 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04679012 2025-10-07

Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation

Phase 2 Recruiting

20 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT00812669 2025-07-08

CLL-Irl Study. CTRIAL-IE (ICORG) 07-01, V7

Phase 2 Completed

52 enrolled

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04189952 2025-05-31

Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma

Phase 2 Terminated

2 enrolled 6 charts

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT00848328 2025-04-24

Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin Lymphoma

Phase 2 Terminated

30 enrolled

Lymphoma, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04666038 2025-04-20

BRUIN CLL-321

238 enrolled 17 charts 3 FDA

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT04494503 2025-04-16

Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL

Phase 1/2 Recruiting

123 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03492125 2025-04-10

A Study Of The Selective PKC-β Inhibitor MS- 553

Phase 1/2 Terminated

60 enrolled 20 charts

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03615105 2025-04-06

Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors

Phase 2 Terminated

9 enrolled 11 charts

Hodgkin Disease, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04419389 2025-03-17

R/R

Phase 1/2 Terminated

1 enrolled 4 charts

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT00769522 2024-12-31

FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia

Phase 3 Completed

564 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02950051 2024-12-30

GAIA

Phase 3 Completed

926 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03524235 2024-11-12

Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL

Phase 1 Completed

20 enrolled

Hodgkin Disease, Lymphoma, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasm, Residual

NCT03788291 2024-09-26

Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

Phase 2 Completed

39 enrolled 8 charts